916
Helvetica Chimica Acta – Vol. 92 (2009)
(1RS,2RS,4RS)-4,5-{[Bis(1,1-dimethylethyl)silylene]dioxy}-1,2,3,4-tetrahydronaphthalene-1,2-diyl
Diacetate (¼(3aRS,5RS,6RS)-2,2-Bis(1,1-dimethylethyl)-3a,4,5,6-tetrahydronaphtho[1,8-de]-1,3,2-dioxa-
silin-5,6-diol Diacetate; 24). As described for 23, with 19 (14 mg, 0.0417 mmol) in dry CH2Cl2 (2 ml),
DMAP (1.5 mg, 0.0125 mmol), and Ac2O (39 ml, 0.417 mmol): 12 mg (70%) of 24. White solid. Rf
(AcOEt/hexane 3 :7) 0.44. IR (KBr): 2963, 2934, 2860, 1747, 1602, 1584, 1474, 1368, 1247, 1227. 1H-NMR
(400 MHz, CDCl3): 0.96 (s, Me3C); 1.16 (s, Me3C); 2.05 (s, MeCOO); 2.11 (s, MeCOO); 2.12 – 2.18 (m,
1 H, CH2(3)); 2.51 (ddt, J ¼ 1.2, 4.3, 13.9, 1 H, CH2(3)); 5.18 (dd, J ¼ 5.9, 10.6, HꢀC(4)); 5.23 (ddd, J ¼
2.8, 5.8, 7.0, HꢀC(2)); 5.87 (d, J ¼ 2.7, HꢀC(1)); 6.93 – 6.95 (m, HꢀC(6), HꢀC(7)); 7.22 (dt, J ¼ 0.6, 8.0,
HꢀC(8)). 13C-NMR (100 MHz, CDCl3) 21.45; 21.60; 21.64; 21.92; 27.42; 27.50; 32.51 (C(3)); 65.97
(C(4)); 68.80 (C(1)); 70.44 (C(2)); 119.71; 123.02; 127.95; 129.58 (C(7)); 132.34; 154.44 (C(5)); 170.25;
170.34. ESI-MS (pos.): 443 ([M þ Na]þ).
(1RS,2SR,4SR)-1,2,3,4-Tetrahydro-4,5-dihydroxynaphthalene-1,2-diyl Diacetate (¼(1RS,2SR,6SR)-
1,2,3,4-Tetrahydronaphthalene-1,2,4,5-tetrol 1,2-Diacetate; 25). To a soln. of 23 (90 mg, 0.214 mmol) in
dry THF (5 ml) in a plastic flask at r.t., and dry pyridine (323 ml, 2.97 mmol) and then 70% HF/pyridine
(161 mg, 4.27 mmol) were added by syringe. The mixture was stirred for 30 min, then AcOEt (15 ml) was
added. The mixture was washed with brine (10 ml) and dried (MgSO4), the solvent evaporated, and the
residue purified by CC (SiO2, AcOEt/hexane 1:1): 47 mg (78%) of 25. White solid. M.p. 1418 (hexane/
AcOEt). Rf (AcOEt/hexane 1:1) 0.22. IR (KBr): 3481, 3242, 1734, 1719, 1595, 1471, 1368, 1260, 1229.
1H-NMR (400 MHz, CD3COCD3): 1.99 (s, MeCOO); 2.04 (s, MeCOO); 2.06 – 2.10 (m, 1 H, CH2(3));
2.45 (ddd, J ¼ 5.1, 10.8, 13.4, 1 H, CH2(3)); 3.84 (br., OH); 5.26 (t, J ¼ 4.7, HꢀC(4)); 5.53 (dt, J ¼ 3.3, 10.8,
HꢀC(2)); 6.13 (d, J ¼ 3.4, HꢀC(1)); 6.78 (d, J ¼ 7.7, H ꢀC(6)); 6.88 (dd, J ¼ 1.1, 8.0, HꢀC(8)); 7.19 (t, J ¼
7.8, HꢀC(7)). 13C-NMR (100 MHz, CD3COCD3) 20.44; 20.46; 32.48 (C(3)); 63.58 (C(4)); 67.91 (C(2));
69.07 (C(1)); 116.10 (C(8)); 120.83 (C(6)); 125.33; 129.64 (C(7)); 134.15; 156.27 (C(5)); 170.11; 170.27.
ESI-MS (neg.): 279 ([M ꢀ H]ꢀ). Anal. calc. for C14H16O6 (280.3): C 60.00, H 5.75; found: C 60.14, H 5.91.
(1RS,2RS,4RS)-2-Acetoxy-4,5-dihydroxy-1,2,3,4-tetrahydronaphthalene-1,2-diyl
Diacetate
(¼(1RS,2RS,3RS)-1,2,3,4-Tetrahydronaphthalene-1,2,4,5-tetrol 1,2-Diacetate; 26). As described for 25,
with 24 (15 mg, 0.0286 mmol) in dry THF (2 ml), dry pyridine (76 ml, 0.698 mmol), and 70% HF/pyridine
(25 mg, 0.662 mmol): 5 mg (64%) of 26. White solid. Rf (AcOEt/hexane 1:1) 0.24. 1H-NMR (400 MHz,
CD3COCD3): 2.01 (s, MeCOO); 2.10 (s, MeCOO); 2.26 – 2.29 (m, CH2(3)); 4.74 (br., OH); 5.19 – 5.22
(m, HꢀC(4)); 5.37 – 5.42 (m, HꢀC(2)); 5.92 (d, J ¼ 6.4, HꢀC(1)); 6.75 (d, J ¼ 7.7, H ꢀC(6)); 6.83 (dd, J ¼
1.1, 8.1, HꢀC(8)); 7.18 (t, J ¼ 7.8, HꢀC(7)); 8.86 (br., OH). 13C-NMR (100 MHz, CD3COCD3): 20.43;
20.49; 33.79 (C(3)); 63.77 (C(4)); 69.58 (C(2)); 71.11 (C(1)); 115.75 (C(8)); 119.94 (C(6)); 125.23; 129.48
(C(7)); 134.53; 156.46 (C(5)); 169.77; 170.25. ESI-MS (neg.): 279 ([M ꢀ H]ꢀ).
(1RS,2SR,4SR)-1,2,3,4-Tetrahydronaphthalene-1,2,4,5-tetrol (27). To a soln. of 18 (103 mg,
0.307 mmol) in dry THF (10 ml) in a plastic flask at r.t., dry pyridine (465 ml, 4.27 mmol) and then
70% HF/pyridine (231 mg, 6.11 mmol) were added by syringe. The mixture was stirred for 30 min and
then AcOEt (15 ml) was added. The mixture was poured over SiO2 (1.5 g), the solvent evaporated, and
the residue purified by CC (SiO2, AcOEt): 58 mg (96%) of 27. White solid. Rf (AcOEt) 0.24. 1H-NMR
(400 MHz, CD3OD): 1.95 (ddt, J ¼ 1.0, 3.5, 13.4, 1 H, CH2(3)); 2.30 (ddd, J ¼ 4.8, 11.1, 13.4, 1 H, CH2(3));
4.24 (dt, J ¼ 3.3, 11.1, HꢀC(2)); 4.61 (d, J ¼ 3.5, HꢀC(1)); 5.20 (t, J ¼ 4.2, HꢀC(4)); 6.78 (dd, J ¼ 1.1, 8.0,
HꢀC(8)); 6.91 (dd, J ¼ 0.6, 7.6, HꢀC(6)); 7.17 (t, J ¼ 7.8, HꢀC(7)). 13C-NMR (100 MHz, CD3OD): 34.26
(C(3)); 63.91 (C(4)); 66.67 (C(2)); 70.09 (C(1)); 114.74 (C(8)); 121.16 (C(6)); 124.21; 129.16 (C(7));
138.58; 156.08 (C(5)). ESI-MS (neg.): 195 ([M ꢀ H]ꢀ).
(1RS,2RS,4RS)-1,2,3,4-Tetrahydronaphthalene-1,2,4,5-tetrol (28). As described for 27, with 19
(20 mg, 0.0594 mmol) in dry THF (5 ml) dry pyridine (90 ml, 0.828 mmol), and 70% HF/pyridine
(45 mg, 1.19 mmol): 6 mg (52%) of 28. White solid. As described for 27, with 20 (14 mg, 0.0395 mmol) in
dry THF (1.4 ml), dry pyridine (63 ml, 0.578 mmol), and 70% HF/pyridine (32 mg, 8.48 mmol) but for 2 h
30 min: 4.4 mg (57%) of 28. White solid. Rf (AcOEt) 0.15. 1H-NMR (400 MHz, CD3OD): 1.92 (ddd, J ¼
4.5, 11.0, 13.5, 1 H, CH2(3)); 2.22 (dt, J ¼ 3.6, 13.5, 1 H, CH2(3)); 4.05 (ddd, J ¼ 3.3, 7.8, 11.0, HꢀC(2));
4.33 (d, J ¼ 7.7, H ꢀC(1)); 5.15 (t, J ¼ 4.1, HꢀC(4)); 6.73 (ddd, J ¼ 0.7, 1.1, 7.9, HꢀC(8)); 7.06 (dt, J ¼ 0.9,
7.8, HꢀC(6)); 7.16 (t, J ¼ 7.9, HꢀC(7)). 13C-NMR (100 MHz, CD3OD): 37.25 (C(3)); 63.48 (C(4)); 68.96
(C(2)); 74.44 (C(1)); 113.90 (C(8)); 118.63 (C(6)); 124.04; 129.10 (C(7)); 139.71; 155.82 (C(5)). ESI-MS
(neg.): 195 ([M ꢀ H]ꢀ).